Fresenius Medical Care AG & Co. KGaA (FMS) Projected to Post Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is expected to be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings of $0.67 per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 6:00 AM ET.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.1%

Shares of NYSE FMS opened at $24.44 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $23.24 and its two-hundred day moving average is $24.48. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $20.94 and a 52-week high of $30.46. The firm has a market cap of $14.17 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.77 and a beta of 0.90.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on FMS. Weiss Ratings lowered Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Five investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $28.00.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently modified their holdings of FMS. Brooklyn Investment Group lifted its stake in Fresenius Medical Care AG & Co. KGaA by 5.4% during the fourth quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock worth $212,000 after purchasing an additional 450 shares during the last quarter. Virtus Advisers LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the third quarter worth approximately $290,000. Russell Investments Group Ltd. raised its holdings in Fresenius Medical Care AG & Co. KGaA by 39.0% during the third quarter. Russell Investments Group Ltd. now owns 7,081 shares of the company’s stock worth $186,000 after purchasing an additional 1,985 shares in the last quarter. Orion Porfolio Solutions LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter worth approximately $225,000. Finally, Quantbot Technologies LP acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at $120,000. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.